Galletly C A, Clark C R, McFarlane A C, Weber D L
University of Adelaide, South Australia, Australia.
Psychiatr Serv. 1999 Jan;50(1):101-3. doi: 10.1176/ps.50.1.101.
Clozapine is generally used for patients meeting criteria for treatment resistance. In this study clozapine was given to 19 patients with schizophrenia who did not meet these criteria and whose symptoms were mild to moderate in severity. Clozapine was associated with significant improvement in positive and negative symptoms and quality of life. A more modest improvement on a range of tests of cognitive functioning was also noted. These results suggest that consideration should be given to broadening the usual criteria for patients' eligibility for clozapine treatment.
